The estimated Net Worth of Jeannine Lynch is at least $412 millier dollars as of 31 August 2023. Jeannine Lynch owns over 9,529 units of Rewalk Robotics Ltd stock worth over $388,818 and over the last 3 years Jeannine sold RWLK stock worth over $23,314.
Jeannine has made over 2 trades of the Rewalk Robotics Ltd stock since 2022, according to the Form 4 filled with the SEC. Most recently Jeannine sold 9,529 units of RWLK stock worth $6,575 on 31 August 2023.
The largest trade Jeannine's ever made was selling 20,168 units of Rewalk Robotics Ltd stock on 31 August 2022 worth over $16,739. On average, Jeannine trades about 5,939 units every 73 days since 2021. As of 31 August 2023 Jeannine still owns at least 370,303 units of Rewalk Robotics Ltd stock.
You can see the complete history of Jeannine Lynch stock trades at the bottom of the page.
Jeannine's mailing address filed with the SEC is C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., P.O. BOX 161, YOKNEAM ILIT, L3, 20692203.
Over the last 9 years, insiders at Rewalk Robotics Ltd have traded over $7,660,045 worth of Rewalk Robotics Ltd stock and bought 8,170,475 units worth $6,701,652 . The most active insiders traders include Global Fund Ii Lp Lind Glob..., Glenn P Muir et Wayne Weisman. On average, Rewalk Robotics Ltd executives and independent directors trade stock every 26 days with the average trade being worth of $88,081. The most recent stock trade was executed by Global Fund Ii Lp Lind on 17 November 2023, trading 54,917 units of RWLK stock currently worth $40,089.
exoskeleton leader rewalk robotics, inc. (formerly argo medical technologies) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury (sci). rewalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. founded in 2001, rewalk has headquarters in the us, israel and germany. rewalk robotics' rewalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury (sci) to stand upright and walk. rewalk is the only exoskeleton with fda clearance via clinical studies and extensive performance testing for personal use rewalk has been tested extensively in the u.s., europe, and israel. the rewalk system is supported by the most published data of all exoskeleton systems in the rehabilitation market, and is used by more people worldwide than all other exoskeleton systems combined. the company offers two products: rewalk personal and the
Rewalk Robotics Ltd executives and other stock owners filed with the SEC include: